Neoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy.

Langenhuijsen, Johan F

Neoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy. [electronic resource] - Urologic oncology - 52-7 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article

1873-2496

10.1016/j.urolonc.2009.03.024 doi


Aged
Androgen Antagonists--therapeutic use
Buserelin--therapeutic use
Chemotherapy, Adjuvant
Cohort Studies
Drug Therapy, Combination
Fertility Agents, Female--therapeutic use
Humans
Imidazolidines--therapeutic use
Male
Middle Aged
Neoadjuvant Therapy
Neoplasm Staging
Prostatic Neoplasms--drug therapy
Survival Rate
Time Factors
Treatment Outcome